

**Harvard Medical School/Harvard School of Dental Medicine
Format for the Curriculum Vitae**

Date Prepared: February 1, 2022
Name: Randall Mark Zusman, MD, FACC
Office Address: Massachusetts General Hospital, Yawkey Center for Outpatient Care,
Suite 5B-5800, Boston, MA 02114
Home Address: 99 Needham Street, #1310, Newton, MA 02461
Work Phone: 617-7267790
Work Email: rzusman@partners.org
Work FAX: 617-7267766
Place of Birth: Detroit, Michigan

Education

1969	B.S. Chemistry with Highest Honors, Phi Beta Kappa	Chemistry	University of Michigan, Ann Arbor, Michigan
1973	M.D.	Medicine	Yale University School of Medicine, New Haven, CT

Board Certifications

1976	American Board of Internal Medicine - Internal Medicine
1983	American Board of Internal Medicine - Cardiovascular Diseases

Postdoctoral Training

7/73-6/74	Intern	Medicine	Massachusetts General Hospital, Boston, MA
7/74-6/75	Junior Assistant Resident	Medicine	Massachusetts General Hospital, Boston, MA
7/73-6/75	Clinical Fellow	Medicine	Harvard Medical School, Boston, MA
7/75-6/77	Clinical Associate	Hypertension/Endocrinology, Cardiology	National Heart, Lung and Blood Institute, Hypertension-Endocrine Branch, National Institutes of Health, Bethesda, MD

7/77-12/77	Senior Assistant Resident	Medicine	Massachusetts General Hospital, Boston, MA
1/78-12/78	Chief Resident in Medicine	Medicine	Massachusetts General Hospital, Boston, MA
7/77-12/78	Clinical Fellow	Medicine	Harvard Medical School, Boston, MA
1/79-6/80	Clinical and Research Fellow	Cardiology	Massachusetts General Hospital, Boston, MA
1/79-6/80	Research Fellow	Cardiology	Harvard Medical School, Boston, MA

Faculty Academic Appointments

1/78-6/80	Instructor	Medicine	Harvard Medical School, Boston, MA
7/80- 12/93	Assistant Professor	Medicine	Harvard Medical School, Boston, MA
1/94 -	Associate Professor	Medicine	Harvard Medical School, Boston, MA

Appointments at Hospitals/Affiliated Institutions

7/80– 12/84	Assistant	Medicine	Massachusetts General Hospital, Boston, MA
7/80-6/83	Consultant	Medicine	Massachusetts Eye and Ear Infirmary, Boston, MA
1/85-12/88	Assistant Physician	Medicine	Massachusetts General Hospital, Boston, MA
1/89-12/08	Associate Physician	Medicine	Massachusetts General Hospital, Boston, MA
1/09 -	Physician	Medicine	Massachusetts General Hospital, Boston, MA
7/01 -6/16	Consultant	Cardiology	Massachusetts General Hospital, Boston, MA Medical Department, Massachusetts Institute of Technology, Cambridge, MA

Major Administrative Leadership Positions

Local			
1981-83	Director		Hypertension Clinic, Cardiac Unit, Massachusetts General Hospital, Boston, MA
1982-89	Director		Hypertension Division, Cardiac Unit, Massachusetts General Hospital, Boston, MA

1983-89	Director	Hypertension Associates, Cardiac Unit, Massachusetts General Hospital, Boston, MA
1982-	Director	Hypertension Section, Cardiology Division, Medical Services, Massachusetts General Hospital, Boston, MA
1992-99	Director	Cardiac Rehabilitation Program, Spaulding Rehabilitation Hospital, Boston, MA

Committee Service

Local

1978-2017	Internship Selection Committee 2008-9 Subcommittee Co-Chairman 2010-16 Subcommittee Chairman	Medical Services, Massachusetts General Hospital
1979-83	Subcommittee for the Review of Research Proposals	Committee on Research, Massachusetts General Hospital
1982-1986	Scientific Advisory Committee	General Clinical Research Center, Massachusetts General Hospital
2009-	Scientific Advisory Committee	Office of Research and Career Development, Massachusetts General Hospital

Professional Societies

1973-1991	American Federation for Clinical Research	
1981-1990		Member, Public Policy Committee
1982		Co-Chairman, Public Policy Committee
1983-1986		Chairman, Public Policy Committee
1989-1990		Chairman, 50 th Anniversary Membership Campaign
1976-	American Society of Nephrology	Member
1978-	American Heart Association	Member
1988-	American Society of Hypertension	Member
1999-		Clinical Specialist in Hypertension (Inaugural Designee)
2009-		Association of Hypertension Specialists (Inaugural Designee)
1990-	American College of Cardiology	Fellow
2015-2016	Paul Dudley White Society	Secretary

Editorial Activities

Ad hoc Reviewer: New England Journal of Medicine, Circulation, Journal of Clinical Investigation, Hypertension, American Journal of Hypertension, Journal of the American College of Cardiology, American Journal of Cardiology, Journal of the

American Society of Hypertension, Circulation Research, American Journal of Medicine, Kidney International, Journal of Complementary and Alternative Medicine, American Journal of Physiology, and others.

Editorial Boards:

- 1981-1984 Associate Editor, Prostaglandins, Section on Clinical Pharmacology
- 1981-1983 Associate Editor, Clinical Research, American Federation for Clinical Research
- 1983-1988 Associate Editor, Hypertension
- 1983-1984 Editor-elect, Clinical Research, American Federation for Clinical Research
- 1984-1989 Editor, Clinical Research, American Federation for Clinical Research
- 1985-1987 Editorial Board, Journal of Clinical Hypertension
- 1990-1993 Editorial Board, Journal of Hypertension
- 1996-2001 Editorial Advisory Board, Reviews in Contemporary Pharmacotherapy
- 1999-2004 Editorial Board, Preventive Cardiology Clinic, Cardiology Review
- 2001-2006 Editorial Advisory Board, Managed Care
- 2002- Contributing Guest Editor-Health and Medicine; ABC.com
- 2009 Editorial Review Board, Journal of Applied Research in Clinical and Experimental Therapeutics
- 2015- Advisory Board, Cardiology and Therapy

Honors and Prizes

- 1966 Phi Eta Sigma
- 1968 Phi Lambda Upsilon

- 1969 Phi Beta Kappa
- 1972 Alpha Omega Alpha
- 1973 Louis B. Nahum Prize for Cardiovascular Research,
 Yale University School of Medicine
- 1974 Sigma Xi
- 1980-1985 Established Investigator, American Heart Association
- 1999 Specialist in Clinical Hypertension, American Society of Hypertension

Report of Funded and Unfunded Projects

RECOR – The Solo and Trio Trials – Studies of renal denervation therapy in patients with untreated hypertension, or hypertension resistant to triple drug therapy, respectively. (Randall M. Zusman, MD, and Joseph Garasic, MD, Co-principal Site Investigators)

Report of Local Teaching and Training

Teaching of Students in Courses

- | | | |
|-----------|--|--|
| 2007-2012 | HST 350 Pharmacology and Clinical Therapeutics –Guest Lecturer – one 3-hour lecture/yr, Topic: Evaluation and Treatment of Patients with Hypertension; 50 -75 Fourth year HMS/HST students | Harvard Medical School, Boston, MA and Massachusetts Institute of Technology Health Science and Technology Curriculum, Cambridge, MA |
| 2009- | Cardiology Fellowship Core Curriculum, Lecturer, Topic: Evaluation and Treatment of Patients with Hypertension; 20 -30 Cardiac fellows, residents, students and nurse practitioners; one 1-hour lecture per year | Cardiology Division, Medical Services, Massachusetts General Hospital, Boston, MA |

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

- | | | |
|-------|---|---|
| 1980- | Attending Physician
Cardiac Consultation Service (2 weeks/year: 2 fellows, 2 – 4 residents, and 2 - 4 students)
Cardiac Step-Down Unit Service (2 weeks/year: 2 fellows, 6 residents) | Cardiology Division, Medical Services, Massachusetts General Hospital, Boston, MA |
|-------|---|---|

**Cardiac Outpatient Service (Four 4-
hour sessions/year: 8 – 12
fellows/residents)**

Formal Teaching of Peers (e.g., CME and other continuing education courses)

- 1980 - Harvard Medical School Continuing Medical Education Courses for physicians, Boston, MA. One lecture per course on the “Treatment and Evaluation of Patients with Hypertension”
-presented in review courses in Internal Medicine, Cardiology, Vascular Medicine, Vascular Surgery, and/or Emergency Medicine:
1 – 4 presentations/year.**
- 2006 – 2012 Practicing Clinicians Exchange –continuing medical education Course for nurse practitioners and physician assistants. One lecture per course on “Atherothrombotic Vascular Disease” – 6 courses/year – various locations in the United States.**
- 2006 - 2012 Primary Care Education (PRIMED) – continuing medical Education course for physicians. One lecture per course on “Antiplatelet Therapy and the Treatment of Atherothrombotic Vascular disease” – 6 course per year – various locations in the United States.**

Report of Clinical Activities and Innovations

Current Licensure and Certification

- 1975- Massachusetts License Registration No. 37456
1976 District of Columbia Registration
1988 Maryland License Registration No. D47367
1976 - American Board of Internal Medicine, Internal Medicine
1983 - American Board of Internal Medicine, Cardiovascular Diseases

Practice Activities

- 1980 - Cardiology Clinical Practice Massachusetts General Hospital,
Cardiology Division, Section on Hypertension, Yawkey Center for Outpatient
Care, 55 Fruit Street, Boston, MA**
- 2001-2016 Cardiology Consultation Practice, Massachusetts Institute of
Technology, Medical Department, 77 Massachusetts Avenue, Cambridge, MA**

Report of Technological and Other Scientific Innovations

Renin Inhibitory Peptide –

In collaboration with Dr. Edgar Haber, James Burton, and William Carlson and with the support of the National Aeronautics and Space Administration, we developed a peptide with renin inhibitory properties. This substance, available in exceedingly small quantities, was then used to study the physiology of the renin angiotensin system, the regulation of blood pressure, and the effects of weightlessness (in gravity-free environments) on cardiac and renal physiology. Our work provided the basis for the ultimate development of aliskiren, a recently FDA-approved, orally active renin inhibitor, which is now in use for the treatment of hypertension and being tested for the treatment of congestive heart failure, asymptomatic LV dysfunction, and diabetic nephropathy.

Citations:

Zusman RM, Burton J, Christensen D, Nussberger J, Dodds A, Haber E. Hemodynamic effects of a competitive renin inhibitory peptide in humans: Evidence for multiple mechanisms of action. *Trans Assoc Am Phys* 1983; XCVI:365-374.

Zusman RM, Hui K, Nussberger J, Christensen DM, Higgins J, Carlson WD, Schoenfeld D, Haber E. R-PEP-27, a potent inhibitor, decreases plasma angiotensin II and blood pressure in normal volunteers. *Am J Hypertension* 1984; 7:295-301.

Report of Education of Patients and Service to the Community

Activities

1980 - Consultant/Guest commentator - ABC News, CBS News, NBC News, FOX News, ABC Evening News, CNN News, and National Public Radio

Frequent guest commentator/consultant for on-air stories about health reports on cardiology, hypertension, cardiac risk reduction, stress, etc. Recent contributions include discussions of cardiac risk factors and cardiac risk reduction (CNN News – prompted by the tragic death of Tim Russert, the effects of stress and the economic downturn on cardiovascular health and specifically blood pressure control (FOX News, NBC News), and the role of life-style modification, salt restriction and the relaxation response for the control of hypertension (National Public Radio).

Educational Material for Patients and the Lay Community

Books, monographs, articles and presentations in other media

1. Zusman RM (Consultant Editor). **High Blood Pressure: A Special Report from the Harvard Health Letter**. 2001; Harvard Medical School Health Publications Group, Boston, MA.

2. **Zusman RM (Consultant Editor). High Blood Pressure: A Special Report from the Harvard Health Letter. 2004; Harvard Medical School Health Publications Group, Boston, MA.**
3. **Zusman, RM (Medical Editor). Hypertension: Controlling the ‘silent killer’. A Special Health Report from the Harvard Medical School. 2007; Harvard Health Publications Group, Boston, MA.**
4. **Zusman, RM (Contributor) In Body Signs by Joan Liebmann-Smith, Ph.D. and Jacqueline Nardi Egan, 2007, Bantam Dell Books, New York, NY.**
5. **Zusman, RM (Medical Editor). Hypertension: Controlling the ‘silent killer’. A Special Health Report from the Harvard Medical School. 2009; Harvard Health Publications Group, Boston, MA.**
6. **Zusman, RM (Medical Editor). Hypertension: Controlling the ‘silent killer’. A Special Health Report from the Harvard Medical School. 2011; Harvard Health Publications Group, Boston, MA.**
7. **Zusman, RM (Medical Editor). Hypertension: Controlling Your Blood Pressure-What to do when your doctor says you have hypertension. A Harvard Medical School Special Health Report. 2014; Harvard Health Publications Group, Boston, MA**
8. **Zusman, RM (Medical Editor). Hypertension: Controlling Your Blood Pressure-What to do when your doctor says you have hypertension. A Harvard Medical School Special Health Report. 2018; Harvard Health Publications Group, Boston, MA.**

Recognition

2007	America’s Top Doctors for Men	Men’s Health Magazine
2008 - 2022	Boston’s Top Docs-Boston Magazine	
2017-	Citation	Who’s Who in the World
	- 2018 Albert Nelson Marquis Lifetime Achievement Award	
2009-	Citation	Who’s Who in America
1997-2000	Citation	Who’s Who in the East
2009	Nominee – Brian McGovern Award for Clinical Excellence - Massachusetts General Hospital Physicians Organization	
2011	Boston Super Doctors (superdoctors.com)	

- 2011, 2012 **Top Doctors – U.S. News and World Report**
- 2014 **America’s Top Physicians (Showmark)**
- 2017-2019 **Castle Connolly America’s Top Doctors**
- 2018 **Albert Nelson Marquis Who’s Who Lifetime Achievement Award**

Report of Scholarship

Publications

Peer reviewed publications in print or other media

Original Reports:

1. **Zusman RM. Quantitative conversion of prostaglandin A or prostaglandin E to prostaglandin B. Prostaglandins 1972; 1:167-168.**
2. **Zusman RM, Caldwell BV, Speroff L, Behrman H. Radioimmunoassay of the A prostaglandins. Prostaglandins 1972; 2:41-53.**
3. **Zusman RM, Forman B, Schneider G, Caldwell BV, Speroff L, Mulrow PJ. The effect of chronic sodium loading and sodium restriction on plasma and renal concentrations of prostaglandin A in normal Wistar and spontaneously hypertensive Aoki rats. Clin Sci Mol Med 1973; 45(Suppl. 1): 325S-329S.**
4. **Zusman RM, Spector D, Caldwell BV, Speroff L, Schneider G, Mulrow PJ. The effect of chronic sodium loading and sodium restriction on plasma prostaglandin A, E, and F concentrations in normal humans. J Clin Invest 1973; 52:1093-1098.**
5. **Spector D, Zusman RM, Caldwell BV, Speroff L. The distribution of prostaglandins A, E, and F in the human kidney. Prostaglandins 1974; 6:263-270.**
6. **Auletta FJ, Zusman RM, Caldwell BV. Development and standardization of a radioimmunoassay for prostaglandins E, F and A. Clin Chem 1974; 20:1580-1587.**
9. **Axelrod L, Trzepacz PT, Zusman RM, Martin DB. Antilipolytic effect of prostaglandin E2 analogues: Therapeutic implications. Life Sci 1976; 18:627-632.**
8. **Zusman RM, Axelrod L, Tolkoﬀ-Rubin N. The treatment of hepatorenal syndrome with intra-renal administration of prostaglandin E1. Prostaglandins 1977; 13:812-830.**
9. **Zusman RM, Keiser HR. Prostaglandin biosynthesis by rabbit renomedullary interstitial cells in tissue culture: Stimulation by angiotensin II, bradykinin and arginine vasopressin. J**

Clin Invest 1977; 60:215-223.

- 10. Zusman RM, Keiser HR. Prostaglandin E2 biosynthesis by rabbit renomedullary interstitial cells in tissue culture: Mechanism of stimulation by angiotensin II, bradykinin, and arginine vasopressin. J Biol Chem 1977; 252:2069-2071.**
- 11. Zusman RM, Keiser HR, Handler JS. Vasopressin-stimulated prostaglandin E biosynthesis in the toad urinary bladder: Effect on water flow. J Clin Invest 1977; 60:1339-1347.**
- 12. Zusman RM, Keiser HR, Handler JS. Inhibition of vasopressin-stimulated prostaglandin E biosynthesis by chlorpropamide in the toad urinary bladder: Mechanism of enhancement of vasopressin-stimulated water flow. J Clin Invest 1977; 60:1348-1353.**
- 13. Zusman RM, Keiser HR, Handler JS. A hypothesis for the molecular mechanism of action of chlorpropamide in the treatment of diabetes mellitus and diabetes insipidus. Fed Proc 1977; 36:2728-2729.**
- 14. Zusman RM, Keiser HR, Handler JS. Effect of adrenal steroids on vasopressin-stimulated PGE synthesis and water flow. Am J Physiol 1978; 234:F532-F540.**
- 15. Vinci JM, Gill JR, Jr., Bowden RE, Pisano JJ, Izzo JL, Jr., Radfar N, Taylor AA, Zusman RM, Bartter FC, Keiser HR. The kallikrein-kinin system in Bartter's syndrome and its response to prostaglandin synthetase inhibition. J Clin Invest 1978; 61:1671-1682.**
- 16. Orloff J, Zusman RM. Role of prostaglandin E (PGE) in the modulation of the action of vasopressin on water flow in the urinary bladder of the toad and mammalian kidney. J Membrane Biol 1978; 40:297-304.**
- 17. Zusman RM, Vinci JM, Bowden RE, Horwitz D, Keiser HR. Effect of indomethacin and adrenocorticotrophic hormone on renal function in man: An experimental model of inappropriate antidiuresis. Kid Internat 1979; 15:62-70.**
- 18. Vinci JM, Zusman RM, Izzo JL, Jr., Bowden RE, Horwitz D, Pisano JJ, Keiser HR. Human urinary and plasma kinins: Relationship to sodium-retaining steroids and plasma renin activity. Circ Res 1979; 44:228-237.**
- 19. Vinci JM, Horwitz D, Zusman RM, Pisano JJ, Catt KJ, Keiser HR. The effect of converting enzyme inhibition with SQ20,881 on plasma and urinary kinins, prostaglandin E, and angiotensin II in hypertensive man. Hypertension 1979; 1:416-426.**
- 20. Brown CA, Zusman RM, Haber E. Characterization of an angiotensin-binding site in rabbit renomedullary interstitial cells in tissue culture: Correlation with prostaglandin biosynthesis. Trans Am Assoc Phys 1979; 92:169-174.**
- 21. Cagan LM, Zusman RM, Pisano JJ. Formation of 1a, 1b Dihomoprostaglandin E2 by rabbit renal interstitial cell cultures. Prostaglandins 1979; 18:617-621.**
- 22. Zusman RM, Keiser HR. Regulation of prostaglandin E2 synthesis by angiotensin II,**

potassium, osmolality, and dexamethasone. *Kid Internat* 1980; 17:277-283.

23. **Zusman RM, Brown CA. Role of phospholipase in the regulation of prostaglandin E2 biosynthesis by rabbit renomedullary interstitial cells in tissue culture: Effects of angiotensin II, potassium, hyperosmolality, dexamethasone, and protein synthesis inhibition. In: *Advances in Prostaglandin and Thromboxane Research*. 1980; 6:243-248.**
24. **Brown CA, Zusman RM, Haber E. Identification of an angiotensin receptor in rabbit renomedullary interstitial cells in tissue culture: Correlation with prostaglandin biosynthesis. *Circ Res* 1980; 46:802-807.**
25. **Zusman RM, Crow JW, Cato AE, Tolkoff-Rubin N. Effects of prostaglandin infusions in uremic patients: Hematologic and hemodynamic response. *Clin Pharmacol Ther* 1981; 30:251-257.**
26. **Zusman RM, Rubin RH, Cato AE, Cocchetto DM, Crow JW, Tolkoff-Rubin NE. Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. *N Engl J Med* 1981; 304:934-939.**
27. **Doppelt SH, Slovik DM, Neer RM, Nolan J, Zusman RM, Potts JT, Jr. Gut mediated hypercalcemia in rabbits bearing the VX2 carcinoma: A new mechanism for tumor-induced hypercalcemia. *Proc Natl Acad Sci USA* 1982; 79:640-644.**
28. **Khosla S, Kinter LB, Zusman RM, Beeuwkes R, III. ACTH and indomethacin-induced antidiuresis in low salt Brattleboro strain rats: Induction and escape. *Annals New York Academy Science* 1982; 394:265-269.**
29. **Zusman RM, Burton J, Christensen D, Nussberger J, Dodds A, Haber E. Hemodynamic effects of a competitive renin inhibitory peptide in humans: Evidence for multiple mechanisms of action. *Trans Assoc Am Phys* 1983; XCVI:365-374.**
30. **Ausiello DA, Zusman RM. The role of calcium in the stimulation of prostaglandin synthesis by vasopressin in rabbit renal-medullary interstitial cells in tissue culture. *Biochem J* 1984; 220:139-145.**
31. **Fulghum TG, DiMarco JP, Supple EW, Nash I, Gendlerman J, Eton DF, Newell JB, Zusman RM, Powell WJ, Jr. Effect of prostacyclin on vascular capacity in the dog. *J Clin Invest* 1985; 76:999-1006.**
32. **Zusman RM, Christensen DM, Kanarek DJ, Kiess MC, Boucher CA. Evaluation of bepridil for the treatment of angina pectoris: Evidence for preservation of left ventricular function. *Am J Cardiol* 1985; 55:30C-35C.**
33. **Hill JA, O'Brien JT, Alpert JS, Gore JM, Zusman RM, Christensen D, Boucher CA, Vetovec G, Borer JS, Friedman C, Mack R, Conti CR, Pepine CJ. Effect of bepridil in patients with chronic stable angina: Results of a multicenter trial. *Circulation* 1985; 71:98-103.**

34. Gold HK, Johns JA, Leinbach RC, Yasuda T, Grossbard E, Zusman RM, Collen D. A randomized double-blind, placebo-controlled trial of recombinant human tissue-type plasminogen activator (RT-PA) in patients with unstable angina pectoris. *Circulation* 1987; 75:1192-1199.
35. Zusman RM. Effects of converting enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: Correlation of chemical structure and biologic activity. *Am J Kid Dis* 1987; 10:I-13-23.
36. Miller DD, Ruddy TD, Zusman RM, Okada RD, Strauss HW, Kanarek DJ, Christensen D, Federman EB, Boucher CA. Left ventricular ejection fraction response to exercise in asymptomatic hypertension. *Am J Cardiol* 1987; 59:409-413.
37. Dimsdale JE, Graham RM, Ziegler MG, Zusman RM, Berry CC. Age, race, diagnosis, and sodium effects on the pressor response to infused norepinephrine. *Hypertension* 1987; 10:564-569.
38. Zusman RM, Christensen DM, Federman EB, Ruddy TD, Miller DD, Boucher CA. Nifedipine, but not propranolol, improves left ventricular systolic and diastolic function in patients with hypertension. *Am J Cardiol* 1989; 64:51F-61F.
39. Zusman RM, Christensen DM, Higgins J, Boucher CA. Nifedipine improves left ventricular function in patients with hypertension. *J Cardiovascular Pharmacol* 1991; 18:843-848.
40. Zusman RM, Christensen DM, Higgins J, Boucher CA. Effects of fosinopril on cardiac function in patients with hypertension: Radionuclide assessment of left ventricular systolic and diastolic performance. *Amer J Hypertension* 1992; 5:219-223.
41. Zusman RM, Christensen DM, Higgins J, Boucher CA. Effects of anti-anginal therapy on left ventricular systolic and diastolic performance: Comparison of the response to bepridil, diltiazem and propranolol. *Amer J Cardiol* 1992; 69:25D-30D.
42. Zusman RM, Christensen DM, Higgins J, Boucher CA. Comparison of the cardiac and hemodynamic effects of lisinopril and atenolol in patients with hypertension: Therapeutic implications. *J Cardiovasc Pharmacol* 1992; 20:216-222.
43. Zusman RM. Left ventricular hypertrophy and performance: Therapeutic options among the angiotensin-converting enzyme inhibitors. *J Cardiovasc Pharmacol* 1992; 20(Supp 10):S21-S28.
44. Zusman RM, Higgins J, Christensen DM, Boucher CA. Bepridil improves left ventricular performance in patients with angina pectoris. *J Cardiovasc Pharmacol*, 1993; 22:474-480.
45. Zusman RM, Hui K, Nussberger J, Christensen DM, Higgins J, Carlson WD, Schoenfeld D, Haber E. R-PEP-27, a potent inhibitor, decreases plasma angiotensin II and blood pressure in normal volunteers. *Am J Hypertension* 1994; 7:295-301.
46. Zervos G, Zusman RM, Swindle LA, Alpert NM, Fischman AJ, Gewirtz H. Effect of

nifedipine on myocardial blood flow and systolic function in humans with ischemic heart disease. *Coronary Artery Disease* 1999; 10: 185-194.

47. Tawakol A, Azi, K, Migrino R, Watkowska J, Zusman R, Alpert NM, Fischman AJ, and Gewirtz H, Effects of Sildenafil on Myocardial Blood Flow in Humans with Ischemic Heart Disease, *Coronary Artery Disease* 2005; 16:443-449.
48. Wilens, T., Zusman, R., Hammerness, P., Podolski, A., Whitley, J., Spencer, T., Gignac, M., and Biederman, J. An Open –Label Study of the Tolerability of Mixed Amphetamine Salts in Adults with Attention-Deficit/Hyperactivity Disorder and Treated Primary Essential Hypertension. *J Clin Psychiatry*, 2006; 67: 696-702.
49. Hammerness P, Zusman R, Systrom D, Surman C, Baggish A, Schillinger M, and Wilens T. A Pilot Cardiovascular Study of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD), *World J Biological Psychiatry*, 2012, ePub.

Clinical Communications (Peer-Reviewed) [* = principal site investigator at the MGH]

1. Cronin CM, Mitrano EA, Wilder RS, Harmon EP, Zusman RM. Comparative evaluation of the three commercially available transdermal nitroglycerin delivery systems. *Drug Intelligence and Clinical Pharmacy* 1987; 21:642-644.
2. Zusman RM, Christensen D, Federman E, Kochar M, McCarron D, Proush J. Comparison of nifedipine and propranolol used in combination with diuretics for the treatment of hypertension. *Am J Med* 1987; 82(3B)37-41.
3. Bolzano K, Arriaga J, Bernal R, Bernardes H, Calderon JL, Debruyne J, Dienstl F, Drayer J, Goodfriend TL, Gross W, Guthrie GP, Holwerda N, Klein W, Krakoff L, Liebau H, Oparil S, Reams GP, Reed WG, Safar M, Schubotz R, Seedat YK, Thind GS, Veriava Y, Wollam G, Woods JW, Zusman RM. The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension. *J Cardiol Pharmacol*, Raven Press, New York, 1987; 9(Suppl 3):S43-S47).
4. Zachariah PK, Bonnet G, Chrysant SG, DeBacker G, Goldstein R, Herrera J, Lindner A, Materson BJ, Maxwell MH, McMahan FG, Merrill RH, Paton RR, Rapp AD, Roginsky MS, Seedat YK, Sime F, Vaicaitis JS, Weinberg MS, Zusman RM. Evaluation of antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe hypertension. *J Cardiol Pharmacol*, Raven Press, New York, 1987; 9(Suppl 3):S53-S58.
5. Wolfson P, Abernethy D, DiPette D, Zusman RM. Diltiazem and captopril alone or in combination for treatment of mild to moderate hypertension. *Am J Cardiol* 1988; 62:103G-108G.
6. Goldberg MR, Sushak MS, Rockhold FW, Thompson WL and the Pinacidil vs Prazosin Multicenter Investigator Group (Zusman RM). Vasodilator monotherapy in the treatment of hypertension: Comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin. *Clin Pharm Therapeutics* 1988; 44(1):78-92.*

7. **Rockhold FW, Goldberg MR, Thompson WL and the Pinacidil-Prazosin and Pinacidil-Placebo Research Groups (Zusman RM). Beneficial effects of pinacidil on blood lipids: Comparisons with prazosin and placebo in patients with hypertension. J Lab Clin Med 1989; 114(6):646-654.***
8. **Anderson RJ, Duchin KL, Gore RD, Herman TS, Michaels RS, Nichola PS, Nolen TM, Wolfson P, Wombolt DG, Zusman RM. Once-daily fosinopril, a novel angiotensin-converting enzyme inhibitor, in the treatment of hypertension. Hypertension 1991; 17:636-642.**
9. **Bepidil Collaborative Study Group (Zusman RM). Comparative efficacy and safety of bepridil and diltiazem in patients with chronic stable angina refractory to diltiazem: Double-blind randomized evaluation. Am J Cardiol 1991; 68:306-312.***
10. **Miller WE and the Fosinopril Multicenter Study Group. Randomized double-blind comparison of fosinopril and propranolol added to diuretic therapy for the treatment of moderate-to-severe hypertension. Drug Investigation 1991; 3(Suppl 4):32-37.***
11. **Moye LA, Pfeffer MA, Braunwald E, for the SAVE Investigators (Zusman RM). Rationale, design and baseline characteristics of the survival and ventricular enlargement (SAVE) trial. Am J Cardiol 1991; 68(Suppl):70D-79D.***
12. **Sacks FM, Pfeffer MA, Moye L, Brown LE, Hamm P, Cole TG, Hawkins CM, Braunwald E, for the CARE Investigators (Zusman RM). Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: The cholesterol and recurrent events trial (CARE). Am J Cardiol 1991; 68:1436-1446.***
13. **Zusman RM. SAVE: Long-term captopril use improves survival in acute MI. Cardiovas Disease 1992; 7(10): 31-32.**
14. **Pfeffer MA, Braunwald E, Moye LA, et al. For the SAVE Investigators (Zusman RM). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992; 327(September):669-677.***
15. **St. John Sutton M, Pfeffer MA, Plappert T, et al. For the SAVE Investigators (Zusman RM). Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994; 89:68-75.***
16. **Chrysant SG, Fagan T., Glazer R., and Kriegman, A (for the Benazepril/Hydrochlorothiazide Study Group (Zusman, RM)). Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Archives of Family Medicine 1996; 1:17-24.***
17. **Rouleau, J, Moye LA Pfeffer MA et al for the SAVE investigators (RM Zusman) A comparison of management patterns after acute myocardial infarction in Canada and the University States. N Engl J Med 328: 779-784. 1993***

18. Rutherford, JD, Pfeffer MA, Moye LA et al on behalf of the SAVE investigators (RM Zusman) Effects of captopril on ischemic events after myocardial infarction. Results of the survival and ventricular enlargement trial . *Circulation* 90:1731-1738, 1994*
19. Lamas GA, Flaker G, Mitchell G, et al for the Survival and Ventricular Enlargement Investigators (RM Zusman) The effect of infarct artery patency on prognosis following acute myocardial infarction *Circulation* 92:1101-1109, 1995.*
20. Wilt TJ, Davis BR, Meyers DG, Rouleau JL, Sacks FM (for the CARE investigators (Randall Zusman)). Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240 mg/dl: Baseline results from the Cholesterol and Recurrent Events (CARE) study. *Angiology* 1996; 47:533-40.*
21. Vantrimpont P, Rouleau JL Wun C-c et al for the SAVE investigators Additive beneficial effects of beta-blockers in the survival and ventricular enlargement (SAVE) study: lack of correlation with plasma norepinephrine *J Am Coll Cardiol* 29: 226-236, 1997.*
22. St. John Sutton M, Pfeffer MA, Moye L, et al for the SAVE Investigators. Cardiovascular death and left ventricular remodeling two years after myocardial infarction, baseline predictors and impact of long term use of captopril. Information from the survival and ventricular enlargement (SAVE) trial. *Circulation* 96:3294-3299, 1997.*
23. Mitchell GF, Moye LA, Braunwald et al for the SAVE Investigators (RM Zusman). Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. *Circulation* 96: 4254-4260. 1997.*
24. Hager WD, Davis BR, Riba A et al for the SAVE investigators (RM Zusman) Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction following myocardial infarction: the SAVE study experience. *Am Heart J* 135: 406-413, 1998*
25. Sacks, FM, Moye LA, Davis, et al for the CARE investigators (RM Zusman) Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial *Circulation* 97: 1446-1452, 1998.*
26. Lewis SJ, Sacks FM, Mitchell JS, et al for the CARE Investigators (RM Zusman) Effect of pravastatin on cardiovascular events in women after myocardial infarction: a randomized trial, the Cholesterol and Recurrent Events Trial. *J Am Coll Cardiol* 32: 140 – 146, 1998.*
27. Vantrimpont P, Rouleau JL, Ciampi A et al, for the SAVE investigators. Two-year time course and significance of neurohumoral activation in the survival and ventricular enlargement (SAVE) study. *Eur Heart J* 19:1552-1563, 1998.*
28. Pfeffer MA, Sacks FM, Moye LA, et al for the CARE investigators (RM Zusman). Influence

of baseline lipids on effectiveness of pravastatin in the CARE trial. *J Am Coll Cardiol* 33:125-130, 1999.*

29. Plehn JF, Davis BR, Sacks F, et al for the CARE Investigators (RM Zusman). Reduction in stroke incidence following myocardial infarction with pravastatin: The Cholesterol and Recurrent Events Study *Circulation* 99:216-223, 1999.8
30. Flaker GC, Warnica JW, Sacks FM, et al for the CARE Investigators (RM Zusman). Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations *J Am Coll Cardiol* 34: 106-112, 1999.*
31. Sutton, St. J, Pfeffer MA, Plappert T, Rouleau JL, Moye LA, Dagenais GR, Lamas, GA, Klein M, Sussex, B, Goldman S, et al (for the SAVE study investigators (RM Zusman)) Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. *Circulation* 1994; 89:68-75.*
32. Pfeffer MA, Sacks FM, Moye LA, Brown L, et al. al. For the CARE Investigators (RM Zusman). Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patients. *Am J Cardiol* 1995; 76:98C-106C.*
33. Sacks FM, Pfeffer MA, Moye LA, et al. al. The Effect of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (RM Zusman). *N Engl J Med* 1996; 335:1001-9.*
34. Waldo AL, Camm AJ, deRuyter H. et.al. for the SWORD Investigators (RM Zusman). Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. *Lancet* 1996; 348:9019, pg 7-12.*
35. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A et al. al. for the SAVE Investigators (RM Zusman). Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. *J Am Coll Cardiol* 1997; 2:229-36.*
36. John Sutton M, Pfeffer MA, Moye, L, Plappert T, Rouleau JL, Lamas G, Rouleau J. Parker JO, Arnold MO, Sussex B, Braunwald E for the Save Investigators. Cardiovascular Death and Left Ventricular Remodeling Two Years After Myocardial Infarction – Baseline Predictors and Impact of Long-term Use of Captopril: Information from the Survival and Ventricular Enlargement (SAVE) Trial (RM Zusman). *Circulation* 1997;96: 3294-3299.*
37. Mann J, Julius for the VALUE trial group (Randall Zusman, MD) The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) Trial of cardiovascular events in hypertension. *Rationale and design Blood Pressure* 1998; 7: 176-183.*
38. Plehn, JF, Davis BR, Sacks, FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moye LA, Piller LB, Rutherford J, Simpson LM, Braunwald E, for the Care Investigators. (RM Zusman). Reduction of Stroke Incidence after Myocardial Infarction with Pravastatin – The

Cholesterol and Recurrent Events (CARE) Study. Circulation 1999; 99: 216-223.*

- 39. Goldberg RB, Mellies MJ, Sacks FM et al for the Care Investigators (RM Zusman). Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analysis in the CARE trial. Circulation 1998; 98: 2515-2519.***
- 40. Ridker PM, Rifai N, Pfeffer MA et al for the CARE Investigators (RM Zusman). Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998; 98: 839-845***
- 41. Lewis SJ, Moye LA, Sacks FM et al for the CARE Investigators (RM Zusman). Effect of pravastatin on cardiovascular events in post-myocardial infarction patients aged 65-75 with cholesterol levels in the average range: results from the Cholesterol and Recurrent Events trial. Ann Intern Med 1998; 129:681-689.***
- 42. Sacks FM, Ridker PM (for the CARE Investigators (RM Zusman)Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Herz 1999; 24:551-56.***
- 43. Sacks FM, Pfeffer MA, Moye LA et al for the CARE Investigators(RM Zusman). . Cholesterol and Recurrent Events Trial (CARE): The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. In Grundy SM Ed, Cholesterol-lowering therapy: evaluation of clinical trial evidence. New York, Marcel Dekker. 2000: 63-90.***
- 44. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Braunwald E (for the CARE Investigators (RM Zusman).) Long term effects of pravastatin on plasma concentration of C-reactive protein Circulation 1999; 100:230-235.***
- 45. Kloner RA, Zusman RM. Cardiovascular Effects of Sildenafil Citrate and Recommendations for Its Use. American Journal of Cardiology 1999; 84 (5B): 11N-17N.**
- 46. Pfeffer MA, McMurray J, Leizorovicz A, et al. for the VALIANT trail investigators (R. M. Zusman) Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000; 140:727-50.***
- 47. Pitman RK, Sanders KM, Zusman RM, Healy AR, Cheema F, Lasko NB, Cahill L, Orr SP. Pilot Study of Secondary Prevention of Post-Traumatic Stress Disorder with Propranolol, Biological Psychiatry 2002; 51:189-192.**
- 48. Kjeldsen, SE, Julius S, Brunner H, Hansson L, Henis M, Ekman S, Laragh J, McInnes, G, Smith B, Weber M and Zanchetti A for the VALUE Trial Group (RM Zusman). Characteristics of 15314 Hypertensive Patients at High Coronary Risk. The VALUE Trial. Blood Pressure 2001, 10:83-91.***
- 49. Fox, KM, Thadani U, Ma, PTS, Nash, SD, Keating Z, et al (On behalf of the CAESAR I Investigators (RM Zusman) (Clinical American and European Studies of Angina and**

Revascularization, Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina European Heart Journal, 2003; 24:2206-2012.*

- 50. Palmer, R, Weiss, R , Zusman RM, Haig A, Flavin,S, and MacDonald B. Effects of Nabumetone, Celecoxib, and Ibuprofen on Blood Pressure Control in hypertensive Patients on ACE Inhibitors, American Journal of Hypertension, 2003; 16:135-139.**
- 51. Viberti, G, Kahn, S, Greene, DA, Herman, WH, Zinman, B, Holman, RR, Haffner, SM, Levy, JM, Berry, RA, Heise, MA, Jones, NP, and Freed, MI (for the ADOPT study investigators(RM Zusman)). A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care, 2002; 25(10), 1737-1743.***
- 52. Pfeffer, MA, McMurray JJV, Velazquez EJ, Rouleau, J-L, Kober L, Maggioni AP, Solomon SC, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA and Califf RM for the Valsartan in Acute Myocardial Infarction Trial Investigators (R.M. Zusman) Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both, N Engl J Med 2003; 349:1893-1906.***
- 53. Julius S, Kjeldsen SE, Weber M, Brunner HR Ekman S, Hansson L Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B Zanchetti A (for the VALUE study investigators (RM Zusman)) VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan or amlodipine based regimens: VALUE, a randomized trial Lancet 2004; 363: 2021-2031.***
- 54. Satish Kenchaiah, Barry R. Davis, Eugene Braunwald, Jean-Lucien Rouleau, Gilles R. Dagenais, Bruce Sussex, Richard M. Steingart, Edward J. Brown, Gervasio A. Lamas, David Gordon, Victoria Bernstein, Marc A. Pfeffer for the SAVE Study Investigators (RM Zusman). Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement trial. American Heart Journal 2004; 148: 356-364.***
- 55. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B Zanchetti A for the Value Trial Group (Randall Zusman, MD) Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004; 363:2049-2051.***
- 56. ONTARGET/TRANSCEND Investigators (Randall M. Zusman, MD) Rationale design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials American Heart Journal 148: 52-61, 2004.***

57. **Kalish, LA, Buczynski B, Connell P, Gemmel A, Goertz C, Macklin EA, Pian-Smith, M, Stevens S, Thompson J, Valaskatgis P, Wayne P and Zusman RM. Stop Hypertension with the Acupuncture Research Program (SHARP): Clinical Trial Design and Screening Results. *Controlled Clinical Trials*, 25: 76-103, 2004.**
58. **Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA and Freed MI (for the ADOPT study investigators (RM Zusman)). Phenotypic Characteristics of GAD Antibody-Positive Recently Diagnosed Patients with Type 2 Diabetes in North American and Europe. *Diabetes* 53: 3193-3200, 2004.***
59. **Julius S, Weber MA, Kjeldsen SE, McInnes GT, Zanchetti A, Brunner HR, Laragh J, Schork MA, Hua TA, Amerena J, Balazovjeh I, Cassel G, Herczeg B, Koylan N, Magometschnigg D, Majahalme S, Martrinez F, Oigman W, Seabra Gomes R, Zhu JR (for the Value trial investigators (Randall Zusman, MD) The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving Monotherapy. *Hypertension* 2006; 48: 385-391.***
60. **Dusek, JA, Hibberd, PL, Buczynski B, Chang B-H, Johnston J, Dusek KC, Wohlhueter A, Zusman, RM, Benson, H. Reduced Systolic Blood Pressure and Reduction of Antihypertensive Medications in Older Adults with Relaxation Response Training; A Randomized, Controlled Trial, *Journal of Alternative and Complementary Medicine*, 2008: 14(2): 129-138.**
61. **Macklin, EA, Wayne PA, Kalish, LA, Valaskatgis, P, Thompson J, Pian Smith, M, Zhang Q, Stevens S, Goertz C, Prineas RJ, Buczynski B, Zusman, RM Stop Hypertension with the Acupuncture Research Program (SHARP). Results of a Randomized Controlled Clinical Trial, *Hypertension*, *Hypertension* 2006; 48: 838-845.**
62. **Kahn, SE, Zinman B, Haffner, SM, O'Neill, C, Kravitz, BG, Yu, D, Freed, MI, Herman, WH, Holman, RR, Jones, NP, Lachin, JM, Viberti, GC and ADOPT Study Group (R.M. Zusman, MD) Obesity is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes, *Diabetes* 2006; 55: 2357-2364***
63. **Sleight, P (for the ONTARGET/TRANSCEND Study Investigators (R.M. Zusman, MD)) The ONTARGET/TRANSCEND Trial Programme: Baseline Data, *Acta Diabetologia* 2005: 42:S50-S56.***
64. **Verma, A, Anavekar, NS, Meris, A, Thune, JJ, Arnold, JMO, Ghali, JK, Velazquez, EJ, McMurray, JJV, Pfeffer, MA, and Solomon SD The Relationship between Renal Function and Cardiac Structure, Function and Prognosis after Myocardial Infarction (The VALIANT Echo Study (for the VALIANT study investigators [Randall Zusman]) *J Am Coll Cardiol* 2007; 50: 1238-1245. ***
65. **Yusuf S, Teo KK, Pogue, J, et al for the ONTARGET Investigators (Randall Zusman) Telmisartan, Ramipril or Both in Patients at High Risk for Vascular Events. *N Engl J Med* 2008; 358: 1547-1559.***

66. **Ridker, PM, Fonseca, FA, Genest, J, Gotto, AM, Dastelein, JJ, Khurmi NS, Koenig, W, Libby P, Lorenzatti AJ, Nordestgaard, BG, Shepehrd J, Willerson JT, Glynn RJ for the Jupiter Trial Study Group (Randall Zusman) Baseline Characteristics of Participants in the JUPITER trial: A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy among Individuals with Low Low-Density Lipoprotein Cholesterol and Elevated High –Sensitivity C-Reactive Protein. Am J Cardiol 2007; 100:1659-1664.***
67. **Ridker, P, Danielson, MIA, Fonseca, FAH, Genest, J, Gotto AM, Kastelein,JJP, Koenig, W, Libby, P LOrenzatti, AJ, MacFadyen JG, Nordestgaard, BABG, Shepherd, Willerson, JT, and Glynn RJ for the Jupiter Study Group (Randall Zusman) Rouvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 2008; 359:2195-2207.***
68. **Mann JFE, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, and Yusuf S for the ONTARGET Investigators (Randall Zusman) Renal Outcomes with Telmisartan, Ramipril, or Both in People at High Vascular Risk (the ONTARGET study): a multicentre, randomized, double blind controlled trial. Lancet 2008; 372: 547-553.***
69. **Cukierman-Yaffe, T, Gerstein HC, Anderson C, Zhao F, Sleight P, Hilbrich L, Jackson SH, Yusuf S, and Teo K on behalf of the ONTARGET/TRANSCEND Investigators (Randall Zusman) Glucose Intolerance an Diabetes as Risk Factors for Cognitive Impairment in People at High Cardiovascular Risk: Results from the ONTARGET/TRANSCENT Research Programme Diabetes Res Clin Pract 2009, Jan 19, Epub.***
70. **Serebruany VL, Atar D, Hanley DR for the ONTARGET Investigators (Randall Zusman) Telmisartan and stroke reduction in the ONTARGET trial: Benefit beyond blood pressure lowering? Cerebrovasc Dis. 2008; 26:563-564.***
71. **Bohm M, Baumhakel M, Probstfield JL Schmieder R, Yusuf S, Zhao F Koon T for the ONTARGET/TRANSCEND Investigators (Randall Zusman). Sexual function, Satisfaction and Association of Erectile Dysfunction with Cardiovascular Disease and Risk Factors in Cardiovascular High-Risk Patients: Substudy of the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INTolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) Am Heart J 2007 154: 94-101.***
72. **Telmisartan Randomized Assessment Study in ACE intolerant subjects with Cardiovascular Disease (TRANSCEND) Investigators (Randall Zusman), Yusuf S, Teo K, Anderson C, Pogue J Dyal L, Copland I Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin converting enzyme inhibitors: a randomized controlled trial. Lancet 2008; 372:1174-1183.***
73. **Held C, Gerstein HC, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K for the ONTARGET/TRANSCEND Investigators (Randall Zusman) Glucose levels predict**

hospitalization for congestive heart failure in patients at high cardiovascular risk. *Circulation* 2007; 20: 115: 1371-1375.*

74. Hohnloser SH, Crijns HJGM, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, and Connolly SJ for the ATHENA Investigators (Randall Zusman) Effect of Dronedronarone on Cardiovascular Events in Atrial Fibrillation. *N Engl J Med* 2009; 360: 668-678.*
75. Hammerness, P, Zusman, R, Systrom, D, Surman, C, Baggish, A, Schillinger, M, Shelley-Abrahamson, R, and Wilens, TE A Cardiopulmonary Study of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder, *The World Journal of Biological Psychiatry*, 2012, ePub.
76. Hoge, EA, Worthington, JJ, Nagurney, JT, Chang, Y, Kay EB, Feterowski, CM, Katzman AR, Goietz, JM, Rosasco, ML, Lask, NB, Zusman, RM, Pollack MH, Orr, SP and Pitman, RK. Effect of Acute Posttrauma Propranolol on PTSD Outcome and Physiologic Responses During Script-Driven Imagery. *CNS Neuroscience & Therapeutics* 2011; 1-7
77. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E (for the CARE investigators (Randall Zusman)). Very Low Density Lipoproteins, Apolipoproteins B, CIII, and E and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial. *Circulation* 2000;102:1886-1892.*
78. Sacks FM, Tonkin AM, Craven T, Pfeffer MA, Shepherd J, Keech A, Furberg CD, Braunwald E (for the CARE investigators (Randall Zusman)). Coronary heart disease in patients with low LDL cholesterol: benefit of pravastatin in diabetics and enhanced role of HDL-cholesterol and triglycerides as risk factors. *Circulation* 2002; 105:1424-8.*
79. Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JM, Warnica JW, Flaker GC, Braunwald E, Pfeffer MA. (for the CARE investigators (Randall Zusman)). Predictors of late development of heart failure in stable survivors of myocardial infarction. The CARE study. *J Am Coll Cardiol* 2003;42:1446-53.*
80. Hammerness, R, Zusman, R, Surman, C, McDermott, K, Shelley-Abrahamson, R, Martelon, MK, and Wilens, T. Self-Measure Blood pressure Monitoring in Adults with Attention-Deficit/Hyperactivity Disorder, in preparation.
81. Becker, MC, Wang, TH, Wisniewski, L, et al. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal anti-inflammatory agents in patients with arthritis (for the PRECISION trial investigators) (Randall Zusman) *Am Heart J* 2009: 157:606-612.*
82. Ridker, PM, Pradhan, A, MacFadyen JG, Libby, P, Glynn RJ.[for the JUPITER trial investigators (Randall Zusman)] Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis of the JUPITER trial *Lancet* 2012; 380:565-71.*
83. Moore, JO, Marshall M, Judge, DC, Moss, FH, Gilroy, SJ, Crocker, BJ, Zusman, RM.

Technology-Supported Apprenticeship in the Management of Hypertension: A randomized Controlled Trial *Journal of Clinical Outcomes Management*, 2014, 21: 110-122.

84. **Nissen, SE, Yeomans, ND, Solomon, DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis (for the Precision Trial Investigators) (Randall Zusman)** *N Engl J Med* 2016; 375: 2519-2529.*
85. **Bhasin, MK, Denninger, JW, Huffman JC, Joseph, MG, Niles, H, Chad-Friedman, E, Goldman, R, Buczynski-Kelley, B, Mahoney, BA, Fricchione GL, Dusek, JA, Benson, H, Zusman, RM, Libermann, TA. Specific Transcriptome Changes Associated with Blood Pressure Reduction in Hypertensive Patients After Relaxation Response Training.** *Journal of Complementary and Alternative Medicine*, 2018, 24: 486-504. [Online publication – April 4, 2018 - DOI: 10.1089/acm.2017.0053].
86. **Azizi, M, Schmieder, RE, Mahfoud, F, Weber, MA, Daemen, J, Davies, J, Basile, J, Kirtane, AJ, Wang, Y, Lobo, MD, Saxena, M, Feyz, L, Rader, F, Lurz, P, Sayer, J, Sapoval, M, Levy, T, Sanghvi, K, Abraham, J, Sharp, ASP, Fisher, NDL, Bloch, MJ, Reeve-Stoffer, H, Coleman, L, Mullin C, and Mauri L on behalf of the RADIANCE-HTN Investigators (Randall Zusman) Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicenter, international, single-blind, randomized, sham-controlled trial.** *The Lancet*, 2018; 391:2335-2345. [Online publication – May 23, 2018: DOI:org/10.1016/S0140-6736(18)31082-1
87. **Reed, GW, Abdallah, MS, Shao, M, Wolski, K, Wisniewski, L, Yeomans, N, Luscher, TF, Borer, JS, Graham, DY, Husni, ME, Solomon, DH, Libby, P, Menonn, V, Lincoff, AM, & Nissen, SE (for the PRECISION trial investigators) (Randall Zusman)** *Journal of the American College of Cardiology* 2018; 71: 1741-1751.
88. **Azizi, M, Schmieder, RE, Mahfoud, F, Weber, MA, Daemen, J, Lobo, MD, Sharp ASP, Bloch, MJ, Basile J, Wang, Y, Saxena, M, Lurz, P, Rader, F, Sayer, J, Fisher, NDL, Fouassier, D, Barman, NC, Reeve-Stoffer, H, McClure C, Kirtane, AJ on behalf of the RADIANCE-HTN Investigators (Randall Zusman) Six Month Results of Treatment-Blinded Medication Titration of Hypertension Control Following Randomization to Endovascular ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial,** *Circulation* 2019; 139:2542-2553.
89. **Azizi, M, Sanghvi, K, Saxena, M, et al. on behalf of the RADIANCE-HTN TRIO Investigators (Randall Zusman). Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): A randomized multicentre, single-blind, sham-controlled trial.** *Lancet* (www.lancet.com) - published online May 16, 2021) [[https://doi.org/10.1016/S0140-6736\(21\)00788-1](https://doi.org/10.1016/S0140-6736(21)00788-1)]

Review Articles

1. Hultquist DE, Dean RT, Passon PG, Reed DW, Zusman RM. Catalysis of methemoglobin reduction by the erythrocyte cytochrome B5 - cytochrome B5 reductase system. EMBO Workshop on the Structure and Chemistry of Multicomponent Complexes of Hemoproteins, Paris, France, June 27-29, 1973; 24-25.
2. Zusman RM, Caldwell BV, Mulrow PJ, Speroff L. The role of prostaglandin A in the control of sodium homeostasis and blood pressure. In: Proceedings of the Symposium on "Prostaglandins, Hypertension, and the Kidney", Conference on Recent Progress in Prostaglandins 1973; 3:679-690.
3. Zusman RM, Caldwell BV, Speroff L. A possible control mechanism for the synthesis and release of prostaglandin A from the kidney. In: Proceedings of Symposium on Medical Aspects of Prostaglandins and Cyclic AMP, University of Michigan, Ann Arbor, Michigan (November 1972), Academic Press, 1973; 153-154.
4. Zusman RM, Spector D, Caldwell BV, Speroff L, Schnieder G, Mulrow PJ. The role of prostaglandin A in the regulation of sodium balance and blood pressure in man. In: MP Sambhi, ed. Mechanisms of Hypertension, Proceedings of an International Workshop Conference, Los Angeles, March 7-9, 1973. American Elsevier Publishing Co., Inc., New York, 1973; 274-277.
5. Vinci JM, Zusman RM, Izzo JL, Jr., Bowden RE, Horwitz D, Pisano JJ, Keiser HR. Relationship of human urinary and plasma kinins to sodium-retaining steroids and plasma renin activity. In: S. Fujii, H Moriya, T Suzuki, eds. Kinins II: Systemic Proteases and Cellular Function. Proceedings of International Symposium on Kinins, Tokyo, Japan. (November 6-9, 1978). Plenum Press, Advances Experimental Biology Medicine. 1979; 120B:503-514.
6. Zusman RM, Crow J, Cato A, Tolkoff-Rubin N. Hemodynamic and hematologic effects of prostacyclin in patients with chronic renal failure. In: New Aspects in Anticoagulant Therapy During Extracorporeal Circulation, (D.G. Melrose and S. Moncada, eds.), European Community Press, 1980.
7. Zusman RM. Prostaglandins and water excretion. Annual Review of Medicine. 1981; 32:359-374.
8. Zusman RM. Prostaglandins, vasopressin, and renal water reabsorption. Med Clin North Am 1981; 65:915-926.
9. Khosla S, Kinter LB, Zusman RM, Beeuwkes R. ACTH and indomethacin-induced antidiuresis in low salt Brattleboro strain rats: Induction and escape. Proceedings of International Symposium on the Brattleboro Rat. Valtin H (ed). Dartmouth, New Hampshire, Ann NY Acad Sci 1982; 394:265-269.

10. DeSanctis RW, Zusman RM. Shock. In *Scientific American Medicine*, edited by E. Rubenstein and D. Federman, Scientific American, Inc., New York. 1982; pp 1:III:1-1:III:13.
11. Haber E, Zusman RM, Burton J, Dzau VJ, Barger AC. Is renin a factor in the etiology of essential hypertension? *Hypertension* 1983; 5(Suppl V):V-8-V-15.
12. Zusman RM. Renin- and non-renin-mediated antihypertensive actions of converting enzyme inhibitors. *Kid Internat* 1984; 25:969-983.
13. Dimsdale JE, Pierce C, Schoenfeld D, Brown A, Zusman RM, Graham R. Suppressed anger and blood pressure: The effects of race, sex, social class, obesity and age. *Psychosomatic Med* 1986; 48:430-436.
14. Weber MA, Zusman RM. Ace inhibitors in hypertension. *Drug Therapy* (September), 1986; pp 43-52.
15. Zusman RM. The renin-angiotensin-aldosterone system and cardiovascular medicine. *Clinician* 1988; 6:11-17.
16. Zusman RM. Left ventricular function in hypertension: A factor in selecting antihypertensive drugs. *Postgraduate Medicine* (October 21), 1988; 13-19.
17. Zusman RM. Left ventricular function in hypertension: Relevance to the selection of antihypertensive therapy. *Am J Hypertension* 1989; 2:200S-206S.
18. Zusman RM. Improvement of Left ventricular function: A goal in the treatment of angina pectoris and hypertension. *Primary Cardiology* 1989; 15:47-54.
19. Zusman RM. Alternatives to traditional step-care therapy for hypertension. *Practical Cardiology* 1991; 17:55-70.
20. Rauch SL, Stern TA, Zusman RM. Neuropsychiatric considerations in the treatment of hypertension. *Intl J Psychiatry in Medicine* 1991; 21:291-308.
21. Zusman RM. Myocardial effects of ACE inhibitors: Fosinopril - a new agent. *Family Practice Recertification* 1991; 13(8 Suppl):22-27.
22. Zusman RM. Differential hemodynamic effects of fosinopril. *Proceedings of the Royal Society of Medicine* 1992; 24:18-26.
23. Zusman RM. Left ventricular hypertrophy and performance: Therapeutic options among the ACE inhibitors. *J Cardiol Pharmacol* 1992; 20(Suppl 10): S21-S28.

24. **Zusman RM. Fosinopril and Cardiac Performance. Reviews in Contemporary Pharmacotherapy 1993; 4:25-34.**
25. **Zusman RM. Angiotensin converting enzyme inhibitors: More different than alike? Focus on Cardiac Performance. Amer J Cardiol 1993; 72:25H-36H.**
26. **Zusman RM. Cardiac performance in the hypertensive patient population: Therapeutic considerations. Postgraduate Medicine 1994; (Dec 7):25-32.**
27. **Zusman RM, Morales A, Glasser DB, and Osterloh I. Overall Cardiovascular Profile of Sildenafil Citrate, Amer J Cardiol 1999; 83:35C-44C.**
28. **Zusman, RM, Chesebro JH, Comerota A, et al. Antiplatelet Therapy in the Prevention of Ischemic Vascular Events, Clinical Cardiology, 1999, 22:559-573.**
29. **Zusman, RM. Are all angiotensin receptor blockers alike? American Journal of Hypertension, 1999, 12: 231S-235S.**
30. **Zusman, R.M. Antiplatelet Therapy: Cardiology Perspective. Managed Care 2000, 9 (10): 5 –8.**
31. **Zusman, R.M. Patients with Uncontrolled Hypertension or Concomitant Hypertension and Benign Prostatic Hyperplasia, Clinical Cardiology, 2004, 27: 63-69.**

Book Chapters:

1. **Zusman RM. Regulation of prostaglandin biosynthesis: Studies in the rabbit renomedullary interstitial cell and the toad urinary bladder in vitro. In: A Scriabine, ed. Prostaglandins in Cardiovascular and Renal Physiology. Spectrum Press. 1980; 93-121.**
2. **Zusman RM. Prostaglandin E2 biosynthesis by renomedullary interstitial cells: In vitro studies and pathophysiological corrections. In: AK Mandal, S-O Bohman, eds. The Renal Papilla and Hypertension. Plenum Press, New York, 1980; 187-207.**
3. **Zusman RM. Prostaglandins: Their role in human physiology and disease. In: T Tavill, ed. Biochemical Aspects of Human Disease. Blackwell Scientific Publications Ltd., London, 1983; pp 591-622.**
4. **Zusman RM. Regulation of prostaglandin biosynthesis in cultured renomedullary interstitial cells. In: Prostaglandins and the Kidney. Edited by M.J. Dunn, C. Patrono, and G.A. Cinotti, Plenum Medical Book Company, New York, 1983; pp 17-26.**
5. **Schneller SJ, Zusman RM, Boucher CA. The use of cardiovascular drugs in chronic renal failure. In: R.A. O'Rourke, Cardiovascular Complications of Chronic Renal Failure (Contemporary Issues in Nephrology), 1984; 13:275-306.**

6. Hui KY, Bernatowicz MS, Zusman RM, Carlson W, Haber E, Hartley LH. Statine-containing renin inhibitory peptides: Hemodynamic effects in the primate. In: Deber CM, Hrubby VJ, and Kopple KD. *Peptides: Structure and Function*. Pierce Chemical Company 1985; 771-774.
7. Zusman RM. Eicosanoids: Prostaglandins, thromboxane and prostacyclin. In: Fozzard HA, Haber E, Jennings RB, Katz AM, and Morgan HE (editors). *The Heart and Cardiovascular System*. Raven Press, New York, 1986; pp 1613-1629.
8. Zusman RM. Angiotensin converting enzyme inhibitors: Evidence for renin-dependent and renin-independent mechanisms of action. In: *The Kidney in Hypertension*. Edited by NM Kaplan, BM Brenner, JH Laragh, Raven Press, New York, 1987; pp 161-177.
9. Zusman RM. Hypertensive emergency. In: Parillo J. (ed.) *Current Therapy In Critical Care Medicine*. B.C. Decker, Inc., New York 1987; pp 126-129.
10. Zusman RM, Slater EE, Haber E. Hypertension. In: *The Practice of Cardiology*. KA Eagle, E. Haber, RW DeSanctis, and WG Austen, editors. Little Brown and Company, Boston, 1989; pp 1335-1368.
11. Punzi HA, Zusman RM. Captopril. In: *Cardiovascular Drug Therapy*. Edited by F. Messerli, Saunders WB, Philadelphia, PA, 1990; pp 770-791.
12. Zusman RM. Eicosanoids: Prostaglandins, thromboxane, and prostacyclin. In: Fozzard HA, Haber E, Jennings RB, Katz AM, and Morgan HE (editors). *The Heart and Cardiovascular System*. Raven Press, New York, 1991; pp 1797-1815.
13. Zusman, R.M. Treatment of Hypertensive Emergencies. In Smith, T.W. (editor), *Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease*. W. B. Saunders Company, Philadelphia, 1996; pp. 495-502.
14. Giacalone M. and Zusman, R.M. Hypertension, In Buttaro, TM, Trybulski J, Bailey PP, and Sandberg-Cook J. (editors) *Primary Care: A Collaborative Practice*, Elsevier Mosby, St. Louis, 2013; pp. 556-571

Book Reviews:

1. Zusman RM, Lipson MJ. Clinical cardiac rehabilitation: A cardiologist's guide. *N Engl J Med* 1993; pp 1664.

Case Reports:

1. Zusman, RM, Snider JJ, Cline A, Caldwell BV, Speroff L. Antihypertensive function of a renal- cell carcinoma: Evidence for a prostaglandin-A-secreting tumor. *N Engl J Med* 1974; 290:843-845.

2. Marx SJ, Zusman RM, Umiker WO. Benign breast dysplasia causing hypercalcemia. *J Clin Endo Metab* 1977; 45:1049-1052.
3. Ferrell MA, Doherty D, Zusman RM, Nash IS. Total aortic occlusion caused by sustained balloon inflation: A previously unreported complication of intra-aortic balloon counterpulsation. *Cath Cardiovasc Diag* 1993; 30:211-213.

Editorials:

1. Zusman RM. The expanding role of the basis scientist in clinical medicine. *Clinical Research* 1983; 31:144-145.
2. Zusman RM. Alternatives to traditional antihypertensive therapy. *Hypertension* 1986; 8:837-842.
3. Zusman RM. In defense of alternative antihypertensive therapy. *Hypertension* 1988; 12:327-329.
4. Zusman RM. On the occasion of the Fiftieth Anniversary of the founding of the American Federation for Clinical Research: A look toward the future. *Clinical Research* 1989; 37:173-176.
5. Zusman RM. Alternatives to traditional first-line antihypertensive treatment: Unresolved questions and therapeutic dilemmas - a personal approach. *Hypertension* 1989; 13:(Suppl 1) I-154-I-157.
6. Meller SM, Zusman RM. The Hazy Relationship Between Dietary Sodium Intake and Cardiovascular Mortality: The Health ABC Study. <http://www.acc.org>. February 11, 2016. <http://www.acc.org/latest-in-cardiology/articles/2016/02/11/15/19/the-hazy-relationship-between-dietary-sodium-intake-and-cardiovascular-mortality>
7. Zusman, RM. Perspective: Recall of Valsartan-Containing Products: Clarion Call to Prepare Systematic Response. *American College of Cardiology - Cardiology Magazine*, November, 2018, pages 30-31.

Guest Editorships

1. Zusman RM (Editor), *Cardioprotection by converting enzyme inhibition. (Proceedings of a Symposium at the Twelfth Scientific Meeting of the International Society of Hypertension, Kyoto, Japan). 1988; Excerpta Medica, Princeton, NJ.*
2. Cutler JA, Horan MJ, Roccella EJ, Zusman RM (Guest Editors). *the National Heart, Lung, and Blood Institute Workshop on Antihypertensive Drug Treatment: The Benefits, Costs, and Choices. 1989; Hypertension 13 (Suppl I):I-1-I-172.*
3. Zusman RM (Consultant Editor). *High Blood Pressure: A Special Report from the*

- Harvard Health Letter. 1998; Harvard Medical School Health Publications Group, Boston, MA.
4. **Zusman RM. (Guest Editor) Cardiovascular Effects and Safety of Viagra, American Journal of Cardiology, 1999, 83: 1C-44C.**
 5. **Zusman, RM (Guest Editor) Clinical and Economic Implications of Atherosclerosis Managed Care Best Practice Guidelines: Using Antiplatelet Agents to Lower Risk of Stroke and MI. Managed Care 2000, 9(10): 1-17.**
 6. **Zusman RM (Consultant Editor). High Blood Pressure: A Special Report from the Harvard Health Letter. 2001; Harvard Medical School Health Publications Group, Boston, MA.**
 7. **Zusman RM (Consultant Editor). High Blood Pressure: A Special Report from the Harvard Health Letter. 2004; Harvard Medical School Health Publications Group, Boston, MA.**
 8. **Zusman, RM (Medical Editor). Hypertension: Controlling the ‘silent killer’. A Special Health Report from the Harvard Medical School. 2007; Harvard Health Publications Group, Boston, MA.**
 9. **Zusman, RM (Contributor) In Body Signs by Joan Liebmann-Smith, Ph.D. and Jacqueline Nardi Egan, 2007, Bantam Dell Books, New York, NY.**
 10. **Zusman, RM (Medical Editor). Hypertension: Controlling the ‘silent killer’. A Special Health Report from the Harvard Medical School. 2009; Harvard Health Publications Group, Boston, MA.**
 11. **Zusman, RM (Medical Editor). A Harvard Medical School Special Health Report: Controlling Your Blood Pressure – What to do when your doctor says you have hypertension. 2014; Harvard Health Publications Group, Boston, MA**
 12. **Zusman, RM (Medical Editor). A Harvard Medical School Special Health Report: Controlling Your Blood Pressure – What to do when your doctor says you have hypertension. 2018; Harvard Health Publications Group, Boston, MA, in preparation.**

Professional educational materials or reports, in print or other media

Congressional Testimony:

1. **Zusman RM. Testimony of the AFRCR before the Senate Labor-HHS-Education Appropriations Subcommittee. Clinical Research 1983; 31:386-387.**
2. **Zusman RM. Testimony of the AFRCR before the House Subcommittee on Health and the Environment concerning a joint resolution (HJ Res 136) to direct NIH to fund 6,500 research grants. Clinical Research 1985; 33:411-412.**

Clinical Guidelines and Reports

1. **Cheitlin, DM, Hutter, AM, Brindis, RG, Ganz P, Kaul, S, Russell RO, Zusman, RM. ACC/AHA Expert Consensus Document: Use of Sildenafil (Viagra) in Patients with Cardiovascular Disease Circulation 1999; 99: 168-177 and J Am College Cardiol 1999; 33: 273-82.**
2. **DeBusk, R, Drory, Y, Goldstein, I, Jackson, G, Kaul S, Kimmel, SE, Kostis, JB, Kloner, RA, Lakin, M, Meston, CM, Mittleman, M, Muller, JE, Padma-Nathan, H, Rosen, RC, Stein RA, and Zusman, R. Management of Sexual Dysfunction in Patients with Cardiovascular Disease: Recommendations of the Princeton Consensus Panel. Am J Cardiology 2000; 86:175-181 (Reprinted: Amer J Cardiol 2000;86(2A): 62F – 68F.**
3. **Zusman, RM, Brass, LM, Olin JW, Ballenger, J, Cannon, E, Dresdale, A, Moreo, K, Orland, BI, Rich, SJ, Stemple, C. Using Antiplatelet Agents to Lower Risk of Stroke and MI. Managed Care 2000, 9(10), 1-15.**
4. **Cole, A, Nathan, DM, Savaria-Porter, E, Copeland, P, Turchin, A, Brunt, M, Zusman, R, Barrett, J, Wexler, D, Case, E, McMahon, G, and Mort, E. An Algorithm for the Care of Type 2 Diabetes. Clinical Pathways in Cardiology, 2009, 8:156-165.**

Thesis

1. **Zusman RM. An electron transport system of the human erythrocyte: Methemoglobin reduction via cytochrome B(e). University of Michigan Honors College Senior Thesis, 1969.**
2. **Zusman RM. The role of prostaglandin A in the control of sodium homeostasis and blood pressure. Yale University School of Medicine Thesis, 1973**

Narrative Report

My academic and clinical activities are divided into clinical service (90%), teaching (5%) and administrative responsibilities (5%). My current activities are primarily focused on the care of patients with hypertension, hyperlipidemia (hypercholesterolemia and/or hypertriglyceridemia), pulmonary hypertension, atrial fibrillation, diabetes mellitus, pulmonary hypertension (including

pulmonary arterial hypertension), ischemic heart disease (including coronary artery disease, myocardial infarction, & angina pectoris), cardiomyopathy, congestive heart failure (HFrEF & HFpEF), syncope/palpitations, cardiovascular risk factors, valvular heart disease, vascular disease (including peripheral and carotid vascular disease), as well as other cardiovascular, metabolic, endocrine, and renal disorders. I have a very active outpatient practice devoted to the treatment of patients who are self-referred or are referred by colleagues within the hospital, from the Boston metropolitan area, the New England region, the remainder of the United States and the world. Many of these patients have been classified as “resistant hypertensives” or have been intolerant of previously prescribed anti-hypertensive medications and they are referred for evaluation and for the development of an effective anti-hypertensive regimen, others have marked lipid disorders which have been resistant to standard therapies and/or have been intolerant of those therapies (used to reduce their cardiovascular risk profile).

As a clinician scientist, I have participated in many landmark clinical trials that have established standard of care principles in the treatment of patients with cardiovascular disease. These contributions include the use of pharmacologic therapy as well as non-drug based strategies for the treatment of patients post-myocardial infarction with asymptomatic LV dysfunction, survivors of myocardial infarction with moderate elevations of LDL cholesterol, patients with elevated hs-CRP concentrations to reduce cardiovascular risk, cardiac arrhythmias, and newly diagnosed patients with diabetes mellitus. I have also conducted the largest study of acupuncture performed in the Western world for the treatment of hypertension. My most recent clinical research focused on the determination of the mechanism by which the relaxation response produces a reduction in blood pressure in hypertensive patients.

My teaching responsibilities include formal contributions as an attending physician (Cardiology Consultation Service and Step-Down Unit Visit), classroom lectures in the HST program, and participation in multiple post-graduate CME courses of the Harvard Medical School, as well as Visiting Professor at many hospitals and medical schools around the country. However, one of my most important teaching roles is as a “curbside consultant” to the medical staff, interns, residents and fellows of the MGH who seek my advice on a regular basis regarding the reduction of the cardiovascular risk profile of the patients for whom they are responsible.

I have also focused on activities that promote patient and community education. Through my many appearances on the local and national news, and the publication of the Harvard Medical School Special Health Report on Hypertension, I have, hopefully, contributed in a significant way to the understanding of this disease by the public and helped them to make the changes in their lifestyle and/or to understand the use of their medications to reduce their cardiovascular risk. My career has evolved in a fashion that has led me to a very active clinical practice and to the conduct of clinical research in many areas of cardiovascular risk reduction (hypertension, hyperlipidemia, LV dysfunction, diabetes mellitus, atrial fibrillation), to the study of conventional approaches to blood pressure control (pharmacologic therapy) as well as complementary or alternative medical strategies (acupuncture, relaxation response). I have been involved in technological developments, in study design, and, earlier in my career, in basic science/laboratory research that led to a greater understanding of renal physiology, and blood pressure control. The long term consequences of this effort have been, I hope, a better of understanding of hypertension, hyperlipidemia, and cardiovascular disease, and an improved treatment algorithm for the reduction of cardiovascular mortality and morbidity, in the United States and, indeed, the world.

